What’s inside
View ResearchDelve into the study examining the adaptive-to-innate immune ratio (A/I ratio) and its association with cancer prognosis and response to immunotherapy. This research reveals that a higher A/I ratio correlates with improved survival and better outcomes in immunotherapy, highlighting significant gender differences. The findings suggest the A/I ratio as a potential biomarker for patient stratification and personalized cancer treatment.
Gender Differences in Immune Cell Ratios and Cancer Prognosis
Study shows adaptive-to-innate immune cell ratio varies by gender, impacting cancer prognosis and response to immunotherapy.
Adaptive-to-Innate Immune Ratio and Cancer Survival
Higher adaptive-to-innate immune cell ratio linked to improved survival across multiple cancer types.
Impact of Innate Immune Cells on Cancer Progression
Innate immune cells associated with worse cancer prognosis, highlighting their role in tumor growth and immune evasion.
Gender Bias in Immune Response and Cancer Outcome
Significant gender differences in immune cell infiltration affect cancer outcomes and response to treatments.
Immune Cell Infiltration and Immunotherapy Response
High adaptive-to-innate immune cell ratio predicts better response to checkpoint inhibitor immunotherapy.
Immune System Composition and Metastatic Cancer Survival
Study explores how adaptive and innate immune cell ratios affect survival in metastatic cancer patients.
.svg)
.jpg)
.webp)
